DOCSLIB.ORG

Vilnius University Life Sciences Center. Annual Report 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Life Sciences Center Life Sciences Center Center Sciences Life | Annual Report 2020 Annual Report CONTACT iNfOrmATiON Life Sciences Center Vilnius University Saulėtekio Ave 7, LT-10257 Vilnius, Lithuania Phone: +370 5 223 4435 / +370 5 223 4426 Email: [email protected] www.gmc.vu.lt/en/ Annual Report 2020 CONTENTS FOREWORD | 3 RESEARCH DESCRIPTIONS | 4 Biomolecular Structure & Function | 6 Cell & Molecular Biology | 30 Ecosystems & Biodiversity | 48 Molecular Biotechnologies | 56 Molecular Mechanisms of Disease | 68 Neurobiology | 80 OPEN ACCESS CORE FACILITIES | 86 FACTS & FIGURES | 95 Staff and Students I 96 Financing Sources I 96 International Advisory Council I 97 International Grants I 98 National Projects I 101 Partnership Highlights I 104 Graduate School I 106 Doctoral Theses 2020 I 107 Bachelor and Master Studies I 108 Student Scholarships I 110 Contribution to Overcome COVID-19 Pandemic I 111 International Awards I 114 National Awards I 116 Vilnius University Awards I 118 Scientific Events I 119 Guests I 121 Invited Speakers I 122 Community Events I 123 Public Engagement I 124 Publications in 2020 I 126 List of Patents I 133 Cooperation I 134 Names Index I 136 FOREWORD Year 2020 was both challenging and inspiring. Unexperi- enced in modern times, the deadly pandemic spread fast across the globe reaching Lithuania in early March. Initially it seemed the paralysis and major disruption of the most of our academic activities at the Life Sciences Center of Vilnius University are imminent. In mid-March when the Government announced nationwide quarantine, the lectures and student lab practices were halted and the access to research laboratories was re- stricted. In these circumstances, our community demonstrated strong determination and resilience not to let the academic life stop. Within several days the remote forms of lectures started, and the access to experimental facilities were renewed for stu- dents graduating in 2020. At the beginning of COVID-19 pandemic, Lithuania as other countries experienced a shortage of COVID-19 testing capaci- ties. Within a week, the Temporary Diagnostic Testing Labo- ratory was set up at the Life Sciences Center. After recruiting a team of volunteers and obtaining appropriate certificates from the Government, the PCR-based testing started in April. Throughout the year, more than 20 000 samples with nearly 3 000 diagnosed SARS-Cov-2-positive were tested in our Center. Giant Jamboree which this year was carried out remotely. For During the pandemic, our community members were actively the second time our students won the Grand Prize of the iGEM consulting the Ministry of Health of the Republic of Lithuania as competition. This historic victory proves again and again the well as the President. On request from the Ministry of Health, creativity and academic energy of the students at the Life Sci- the scientists at the Life Sciences Center prepared and validated ences Center. The President the Republic of Lithuania awarded the group testing protocols for COVID-19 patients. For the first our students the historical presidential flag. time the testing of surfaces was developed to track the asymp- We are very proud of our women researchers at the Life tomatic COVID-19 patients. First experimental tests of work- Sciences Center. This year two of them, Dr Rima Bydvytytė and places at the Life Sciences Center revealed the effectiveness Dominyka Dapkutė were granted L’Oréal-UNESCO Baltic For Wo- of the methodology to prevent the infection in organisations men in Science fellowships. Women are becoming more and and public spaces. This contactless technique was later adop- more active in seeking for management positions at the Life ted for COVID-19 testing in kindergartens. For significant contri- Sciences Center. Dr Eglė Lastauskienė was appointed the Di- butions in the fight against OC VID-19 the Life Sciences Center rector of the Institute of Biosciences, which is our major oper- community was awarded letters of gratitude by the Senate and ational unit involved in studies. This appointment reflects the Rector of Vilnius University and honorable awards by the Presi- efforts of our community to ensure gender equality in top man- dent and the Government of the Republic of Lithuania. agement positions at the Life Sciences Center. One of the most important academic events in 2020 was I wish to thank all our academic community for the aca- signing of the agreement between Vilnius University Life Sci- demic year full of unseen challenges. This year will remind us ences Center and the European Molecular Biology Laboratory that all challenges may also provide opportunities to realise our (EMBL). The Life Sciences Center became the 7th remote part- talents and energy for the benefit of society. To take advantage nership institution of EMBL. According to the agreement the of those opportunities we need to continue standing firmly on VU LSC-EMBL Partnership Institute for Genome Editing will be our basic academic values: dedication to excellence in science, established. The funding of the Partnership Institute was se- academic freedom, collegiality and inclusiveness, openness to cured from the Ministry of Education, Science and Sport to start the world and non-discrimination, respect for societal needs six research groups at the Life Sciences Center specializing in and public engagement. These values, I believe, will lead us various fields and applications of CRISPR gene editing systems. towards new success stories in 2021. This year witnessed exceptional achievements of our stu- dents at iGEM international competition in synthetic biology. Addressing an important problem of modern fish farming, which faces a high risk of fish infections our students along with their colleagues from other University departments pre- Gintaras Valinčius pared and remotely presented their project at the annual iGEM Director 3 FACTS & FIGURES RESEARCH DESCRIPTIONS Biomolecular Cell & Molecular Ecosystems & Structure & Function Biology Biodiversity Antiviral Defense Systems in Bacteria I 6 Applications of the Molecular Microbiology Animal Biodiversity, Structure and Bioelectrochemical Systems in of Prokaryotes in Biotechnology and Ecology of Populations I 48 Biopharmacy I 30 Biosensors and Bioreactors I 8 Biodiversity and Ecology of Plants, Algae Biological Modification of DNA and RNA I 10 Applied and Environmental and Fungi I 50 Microbiology I 32 Crystallography and Molecular Environmental Assessment & Ecosystem Modelling I 12 Functioning and Epigenetic Mechanisms of Development I 52 Electrochemical Biosensors for Human Stem Cells I 34 Real-World Applications I 14 Genetic and Structural Diversity of Genotoxicity of Anthropogenic and Bacteriophages I 54 Mechanisms of Flavoenzyme Redox Natural Factors I 36 Reactions I 16 Molecular Mechanisms of Cell Death and Microbial Diversity as a Source of Survival I 38 New Biocatalysts I 18 Molecular Mechanisms of Intracellular Protein Structural Bioinformatics I 20 Trafficking I 39 Protein Structure and Interactions in Phospholipid Membranes I 22 Plant Polymorphism, Genome Stability and Its Changing Factors I 40 Signalling in Prokaryotic Antiviral Defence I 24 Single-Cell Transcriptomics and Single-Molecule Studies of Protein and DNA Genomics I 42 Interactions I 26 Stem Cell Technologies for Bone Tissue Structural Biochemistry I 27 Engineering I 44 Structure and Thermodynamics for Drug Strategies in Antimicrobial Therapy and Design I 28 Protein Engineering I 46 4 OPEN ACCESS CORE FACILITIES Molecular Molecular Mechanisms of Neurobiology Biotechnologies Disease Advanced Microfluidics Technology Antibiotic Resistance and Pathogenesis I 68 Electrophysiological Brain States: Modulating for Biological and Biomedical Factors and Clinical Applications I 80 Epigenomic Studies of Human Disease I 70 Applications I 56 Molecular Signalling Pathways for Synaptic Molecular Mechanisms of Cancer Cell CRISPR-CAS Tools and Technologies I 58 Pruning I 81 Chemoresistance I 71 Biosynthesis of Chimeric and Native Neuroscience and Cellular Biophysics I 82 Genetic and Epigenetic Mechanisms of Cancer Proteins I 60 Development and Progression I 72 Role of Microbiota-Gut-Brain Axis in Development and Application of Molecular Mechanisms of Cancer Cell Neuropsychiatric Disorders I 84 Biocatalytic Systems I 62 Treatment I 74 Evaluation of the Specificity of Genome Molecular Virology: Mechanisms, Evolution, Editing Tools I 64 Antivirals I 76 Generation and Analysis of New Strategies in Fighting the CO VID-19 Antibodies I 65 Pandemic I 77 Molecular Tools for Covalent Labelling Protein Misfolding and Aggregation I 78 and Profiling of Epigenome I 66 5 BIOMOLECULAR STRUCTURE & FUNCTION VirginiJUS ŠIKŠNYS Distinguished Professor Head, Department of Protein-Nucleic Acids Interactions Institute of Biotechnology Email: [email protected] Phone: +370 5 223 4354 Antiviral Defense Systems in Bacteria Phages are the most abundant organisms in the biosphere and the major parasites of bacteria. They infect bacteria in order to replicate and usually kill bacteria when the replication is completed. In response to the phage threat, bacteria developed multiple defence barriers for countering and fighting viral attacks. In the Department of Protein-Nucleic Acids Interactions we aim to understand the structure-function relationships of enzymes and enzyme assemblies that contribute to the bacteria defence systems that target invading nucleic acids. We are particularly interested in the molecular machinery involved in the CRISPR-Cas
Recommended publications
  • (TPZ) Prodrugs for the Management of Hypoxic Solid Tumors by Sindhuja

    (TPZ) Prodrugs for the Management of Hypoxic Solid Tumors by Sindhuja

    Evaluation of bioreductively-activated Tirapazamine (TPZ) prodrugs for the management of hypoxic solid tumors by Sindhuja Pattabhi Raman A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Cancer Sciences Department of Oncology University of Alberta © Sindhuja Pattabhi Raman, 2019 Abstract Solid tumors often have large areas with low levels of oxygen (termed hypoxic regions), which are associated with poor prognosis and treatment response. Tirapazamine (TPZ), a hypoxia targeting anticancer drug, started as a promising candidate to deal with this issue. However, it was withdrawn from the clinic due to severe neurotoxic side effects and poor target delivery. Hypoxic cells overexpress glucose transporters (GLUT) - a key feature during hypoxic tumor progression. Our project aims at conjugating TPZ with glucose to exploit the upregulated GLUTs for its delivery, and thereby facilitate the therapeutic management of hypoxic tumors. We hypothesized that glucose-conjugated TPZ (G6-TPZ) would be selectively recruited to these receptors, facilitating its entrapment in poorly oxygenated cells only, with minimal damage to their oxygenated counterparts. However, our results reveal that the addition of the glucose moiety to TPZ was counterproductive since G6-TPZ displayed selective hypoxic cytotoxicity only at very high concentrations of the compound. We speculate that the reduced cytotoxicity of G6-TPZ might be due to the fact that the compound was not taken up by the cells. In order to monitor the cellular uptake of TPZ, we developed a click chemistry-based approach by incorporating an azido (N3) group to our parent compound (N3-TPZ). We observed that the azido-conjugated TPZ was highly hypoxia selective and the compound successfully tracks cellular hypoxia.
  • Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth

    Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth

    pharmaceuticals Review Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth Paul Hyman Department of Biology/Toxicology, Ashland University, 401 College Ave., Ashland, OH 44805, USA; [email protected]; Tel.: +1-419-207-6309 Received: 28 December 2018; Accepted: 4 March 2019; Published: 11 March 2019 Abstract: For a bacteriophage to be useful for phage therapy it must be both isolated from the environment and shown to have certain characteristics beyond just killing strains of the target bacterial pathogen. These include desirable characteristics such as a relatively broad host range and a lack of other characteristics such as carrying toxin genes and the ability to form a lysogen. While phages are commonly isolated first and subsequently characterized, it is possible to alter isolation procedures to bias the isolation toward phages with desirable characteristics. Some of these variations are regularly used by some groups while others have only been shown in a few publications. In this review I will describe (1) isolation procedures and variations that are designed to isolate phages with broader host ranges, (2) characterization procedures used to show that a phage may have utility in phage therapy, including some of the limits of such characterization, and (3) results of a survey and discussion with phage researchers in industry and academia on the practice of characterization of phages. Keywords: phage therapy; bacteriophage isolation; host range; bacteriophage characterization; genome sequencing; enrichment culture 1. Introduction The isolation of bacteriophages for phage therapy is often presented as a fairly straightforward exercise of mixing a phage-containing sample with host bacteria, followed by a simple removal of bacterial debris by filtration and/or centrifugation the next day [1–3].
  • First Description of a Temperate Bacteriophage (Vb Fhim KIRK) of Francisella Hispaniensis Strain 3523

    First Description of a Temperate Bacteriophage (Vb Fhim KIRK) of Francisella Hispaniensis Strain 3523

    viruses Article First Description of a Temperate Bacteriophage (vB_FhiM_KIRK) of Francisella hispaniensis Strain 3523 Kristin Köppen 1,†, Grisna I. Prensa 1,†, Kerstin Rydzewski 1, Hana Tlapák 1, Gudrun Holland 2 and Klaus Heuner 1,* 1 Centre for Biological Threats and Special Pathogens, Cellular Interactions of Bacterial Pathogens, ZBS 2, Robert Koch Institute, 13353 Berlin, Germany; [email protected] (K.K.); [email protected] (G.I.P.); [email protected] (K.R.); [email protected] (H.T.) 2 Centre for Biological Threats and Special Pathogens, Advanced Light and Electron Microscopy, ZBS 4, Robert Koch Institute, D-13353 Berlin, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-30-18754-2226 † Both authors contributed equally to this work. Abstract: Here we present the characterization of a Francisella bacteriophage (vB_FhiM_KIRK) includ- ing the morphology, the genome sequence and the induction of the prophage. The prophage sequence (FhaGI-1) has previously been identified in F. hispaniensis strain 3523. UV radiation induced the prophage to assemble phage particles consisting of an icosahedral head (~52 nm in diameter), a tail of up to 97 nm in length and a mean width of 9 nm. The double stranded genome of vB_FhiM_KIRK contains 51 open reading frames and is 34,259 bp in length. The genotypic and phylogenetic analysis indicated that this phage seems to belong to the Myoviridae family of bacteriophages. Under the Citation: Köppen, K.; Prensa, G.I.; conditions tested here, host cell (Francisella hispaniensis 3523) lysis activity of KIRK was very low, and Rydzewski, K.; Tlapák, H.; Holland, the phage particles seem to be defective for infecting new bacterial cells.
  • Method of Tumor Treatment

    Method of Tumor Treatment

    Europaisches Patentamt J European Patent Office 0 Publication number: 0 649 658 A1 Office europeen des brevets EUROPEAN PATENT APPLICATION 0 Application number: 94202693.1 mt . ci .6 :A61K 31/53 0 Date of filing: 19.09.94 0 Priority: 22.09.93 US 125609 Palo Alto, CA 94304-1850 (US) 0 Date of publication of application: 0 Inventor: Brown, Martin J. 26.04.95 Bulletin 95/17 c/o Sterling Winthrop, Inc., 90 Park Avenue 0 Designated Contracting States: New York 10016 (US) AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE 0 Representative: Le Guen, Gerard 0 Applicant: THE BOARD OF TRUSTEES OF THE CABINET LAVOIX LELAND STANFORD JUNIOR UNIVERSITY 2, place d'Estienne d'Orves 900 Welch Road, Suite 350 F-75441 Paris Cedex 09 (FR) 0 Method of tumor treatment. 0 The present invention provides methods for increasing the cytotoxicity of a chemotherapy agent towards a solid tumor, such tumor susceptible to treatment with the chemotherapy agent, comprising administering to a mammal having such a tumor, from about one half hour to about twenty-four hours prior to administering the chemotherapy agent, or from about one hour to about two hours after administering the chemotherapy agent, a cytotoxicity-enhancing amount of a compound of Formula I. The invention also provides kits for treatment of such tumors which comprise a chemotherapy agent and a cytotoxicity-enhancing amount of a 1,2,4-ben- zotriazine oxide as defined in Formula I. The present invention also provides the use of a compound of Formula I capable of exerting a cytotoxic- enhancing effect on a cancer tumor for the manufacture of a medicament, for the therapeutic administration to a mammal having such a tumour from about one half hour to about twenty-four hours prior to treatment of said tumor with a chemotherapy agent.
  • Elucidating Viral Communities During a Phytoplankton Bloom on the West Antarctic Peninsula

    Elucidating Viral Communities During a Phytoplankton Bloom on the West Antarctic Peninsula

    fmicb-10-01014 May 10, 2019 Time: 14:46 # 1 ORIGINAL RESEARCH published: 14 May 2019 doi: 10.3389/fmicb.2019.01014 Elucidating Viral Communities During a Phytoplankton Bloom on the West Antarctic Peninsula Tomás Alarcón-Schumacher1,2†, Sergio Guajardo-Leiva1†, Josefa Antón3 and Beatriz Díez1,4* 1 Department of Molecular Genetics and Microbiology, Pontificia Universidad Católica de Chile, Santiago, Chile, 2 Max Planck Institute for Marine Microbiology, Bremen, Germany, 3 Department of Physiology, Genetics, and Microbiology, University of Alicante, Alicante, Spain, 4 Center for Climate and Resilience Research (CR2), University of Chile, Santiago, Chile In Antarctic coastal waters where nutrient limitations are low, viruses are expected to play a major role in the regulation of bloom events. Despite this, research in viral identification and dynamics is scarce, with limited information available for the Southern Ocean (SO). This study presents an integrative-omics approach, comparing variation in the viral and microbial active communities on two contrasting sample conditions from Edited by: a diatom-dominated phytoplankton bloom occurring in Chile Bay in the West Antarctic David Velazquez, Autonomous University of Madrid, Peninsula (WAP) in the summer of 2014. The known viral community, initially dominated Spain by Myoviridae family (∼82% of the total assigned reads), changed to become dominated Reviewed by: by Phycodnaviridae (∼90%), while viral activity was predominantly driven by dsDNA Carole Anne Llewellyn, ∼ ∼ Swansea University, United Kingdom members of the Phycodnaviridae ( 50%) and diatom infecting ssRNA viruses ( 38%), Márcio Silva de Souza, becoming more significant as chlorophyll a increased. A genomic and phylogenetic Fundação Universidade Federal do characterization allowed the identification of a new viral lineage within the Myoviridae Rio Grande, Brazil family.
  • Pioneering Soil Viromics to Elucidate Viral Impacts on Soil Ecosystem Services

    Pioneering Soil Viromics to Elucidate Viral Impacts on Soil Ecosystem Services

    Pioneering Soil Viromics to Elucidate Viral Impacts on Soil Ecosystem Services DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Gareth Trubl Graduate Program in Microbiology The Ohio State University 2018 Dissertation Committee: Virginia Rich, Advisor Matthew Sullivan, Co-Advisor Kelly Wrighton Matthew Anderson Copyrighted by Gareth Trubl 2018 Abstract Permafrost contains 30–50% of global soil carbon (C) and is rapidly thawing. While the fate of this C is unknown, it will be shaped in part by microbes and their associated viruses, which modulate microbial activities via mortality and metabolic control. To date, viral research in soils has been outpaced by that in aquatic environments due to the technical challenges of accessing soil viruses, compounded by the dramatic physicochemical heterogeneity in soils. The Stordalen Mire long-term ecological field site in Arctic Sweden encompasses a mosaic of natural permafrost thaw stages, and has been well characterized biogeochemically and microbiologically, making it an ideal site to characterize the soil virosphere and its potential impacts on the C cycle. A viral resuspension protocol was developed to generate quantitatively- amplified dsDNA viromes. The protocol yielded ~108 virus-like particles (VLPs) g−1 of soil across three thaw-stage habitats, and seven resulting viromes yielded 53 vOTUs. Viral-specific bioinformatics methods were used to recover viral populations, define their gene content, connect them to other related viruses (globally) and potential hosts (locally). Only 15% of these vOTUs had genetic similarity to publicly available viruses in the RefSeq database, and ∼30% of the genes could be annotated, supporting the concept of soils as reservoirs of substantial undescribed viral genetic diversity.
  • Characterization and Genomic Analyses of Two Newly Isolated

    Characterization and Genomic Analyses of Two Newly Isolated

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE www.nature.com/scientificreportsprovided by Lirias OPEN Characterization and genomic analyses of two newly isolated Morganella phages define distant Received: 07 November 2016 Accepted: 09 March 2017 members among Tevenvirinae and Published: 07 April 2017 Autographivirinae subfamilies Hugo Oliveira1,*, Graça Pinto1,*, Ana Oliveira1, Jean-Paul Noben2, Hanne Hendrix3, Rob Lavigne3, Małgorzata Łobocka4,5, Andrew M. Kropinski6 & Joana Azeredo1 Morganella morganii is a common but frequent neglected environmental opportunistic pathogen which can cause deadly nosocomial infections. The increased number of multidrug-resistant M. morganii isolates motivates the search for alternative and effective antibacterials. We have isolated two novel obligatorily lytic M. morganii bacteriophages (vB_MmoM_MP1, vB_MmoP_MP2) and characterized them with respect to specificity, morphology, genome organization and phylogenetic relationships. MP1’s dsDNA genome consists of 163,095 bp and encodes 271 proteins, exhibiting low DNA (<40%) and protein (<70%) homology to other members of the Tevenvirinae. Its unique property is a >10 kb chromosomal inversion that encompass the baseplate assembly and head outer capsid synthesis genes when compared to other T-even bacteriophages. MP2 has a dsDNA molecule with 39,394 bp and encodes 55 proteins, presenting significant genomic (70%) and proteomic identity (86%) but only to Morganella bacteriophage MmP1. MP1 and MP2 are then novel members of Tevenvirinae and Autographivirinae, respectively, but differ significantly from other tailed bacteriophages of these subfamilies to warrant proposing new genera. Both bacteriophages together could propagate in 23 of 27 M. morganii clinical isolates of different origin and antibiotic resistance profiles, making them suitable for further studies on a development of bacteriophage cocktail for potential therapeutic applications.
  • Theranostics Self-Accelerating H2O2-Responsive Plasmonic

    Theranostics Self-Accelerating H2O2-Responsive Plasmonic

    Theranostics 2020, Vol. 10, Issue 19 8691 Ivyspring International Publisher Theranostics 2020; 10(19): 8691-8704. doi: 10.7150/thno.45392 Research Paper Self-accelerating H2O2-responsive Plasmonic Nanovesicles for Synergistic Chemo/starving therapy of Tumors Yao Tang1, Yuejia Ji1, Chenglin Yi2, Di Cheng1, Bin Wang1, Yun Fu1, Yufang Xu1, Xuhong Qian1, Yahya E. Choonara3, Viness Pillay3, Weiping Zhu1, Yunen Liu4 and Zhihong Nie2 1. State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China. 2. State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai 200438, China. 3. Department of Pharmacy and Pharmacology, University of the Witwatersrand, Parktown 2193 Johannesburg, South Africa. 4. Department of Emergency Medicine, the General Hospital of Northern Theater Command, Laboratory of Rescue Center of Severe Trauma PLA, Shenyang l10016, China. Corresponding author: E-mails: [email protected] (Z. Nie); [email protected] (Y. Liu); [email protected] (W. Zhu). © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.02.27; Accepted: 2020.06.17; Published: 2020.07.09 Abstract Rationale: Nanoscale vehicles responsive to abnormal variation in tumor environment are promising for use in targeted delivery of therapeutic drugs specifically to tumor sites. Herein, we report the design and fabrication of self-accelerating H2O2-responsive plasmonic gold nanovesicles (GVs) encapsulated with tirapazamine (TPZ) and glucose oxidase (GOx) for synergistic chemo/starving therapy of cancers.
  • TESIS DOCTORAL Estudio Metagenómico De La Comunidad De

    TESIS DOCTORAL Estudio Metagenómico De La Comunidad De

    TESIS DOCTORAL Estudio metagenómico de la comunidad de virus y de su interacción con la microbiota en la cavidad bucal humana Marcos Parras Moltó Madrid, 2019 Estudio metagenómico de la comunidad de virus y de su interacción con la microbiota en la cavidad bucal humana Memoria presentada por Marcos Parras Moltó para optar al título de Doctor por la Universidad Autónoma de Madrid Esta Tesis se ha realizado en el Centro de Biología Molecular Severo Ochoa bajo la supervisión del Tutor y Director Alberto López Bueno, en el Programa de Doctorado en Biociencias Moleculares (RD 99/2011) Universidad Autónoma de Madrid Facultad de Ciencias Departamento de Biología Molecular Centro de Biología Molecular Severo Ochoa (CBMSO) Madrid, 2019 El Dr. Alberto López Bueno, Profesor Contratado Doctor en el Departamento de Biología Molecular de la Universidad Autónoma de Madrid (UAM) e investigador en el Centro de Biología Molecular Severo Ochoa (CBMSO): CERTIFICA: Haber dirigido y supervisado la Tesis Doctoral titulada "Estudio metagenómico de la comunidad de virus y de su interacción con la microbiota en la cavidad bucal humana” realizada por D. Marcos Parras Moltó, en el Programa de Doctorado en Biociencias Moleculares de la Universidad Autónoma de Madrid, por lo que autoriza la presentación de la misma. Madrid, a 23 de Abril de 2019, Alberto López Bueno La presente tesis doctoral ha sido posible gracias a la concesión de una “Ayuda para Contratos Predoctorales para la Formación de Doctores” convocatoria de 2013 (BES-2013-064773) asociada al proyecto SAF2012-38421 del Ministerio de Economía y Competitividad. Durante esta tesis se realizó una estancia de dos meses en el laboratorio del Catedrático Francisco Rodríguez Valera, director de grupo de investigación: Evolutionary Genomics Group de la Universidad Miguel Hernández de Elche (San Juan de Alicante), gracias a una “Ayuda a la Movilidad Predoctoral para la Realización de Estancias Breves en Centros de I+D” convocatoria de 2015 (EEBB-I-16-11876) concedida por el Ministerio de Economía y Competitividad.
  • Genome Sequence Analysis of Cronobacter Phage PF-CE2 and Proposal of a New Species in the Escherichia Virus RB16 Genus

    Genome Sequence Analysis of Cronobacter Phage PF-CE2 and Proposal of a New Species in the Escherichia Virus RB16 Genus

    Genome Sequence Analysis of Cronobacter Phage PF-CE2 and Proposal of a New Species in the Escherichia Virus RB16 Genus Mengshi Xiao Ocean University of China Xinmiao Ren Ocean University of China Ying Yu Ocean University of China Han Sun Ocean University of China Haijin Mou ( [email protected] ) Ocean University of China https://orcid.org/0000-0003-3667-1562 Xiaodan Fu Ocean University of China Research Article Keywords: Cronobacter sakazakii, Escherichia virus, subsequent heterologous, PF-CE2 glycanase Posted Date: June 21st, 2021 DOI: https://doi.org/10.21203/rs.3.rs-258819/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/10 Abstract The genome of Cronobacter sakazakii M1 phage named PF-CE2 was characterized in this work. And a new species named Cronobacter virus PF-CE2, in the Escherichia virus RB16 genus of the subfamily Tevenvirinae of the family Myoviridae was established. The Gp190 gene of phage PF-CE2 was rst proposed to encode a bacteriophage-borne glycanase, which is capable of degrading fucose-containing exopolysaccharides produced by C. sakazakii M1. Further, the taxonomic status of eight additional phages was modied according to average nucleotide identity analysis. This nding provides a theoretical basis for subsequent heterologous expression of the phage PF-CE2 glycanase and provides an important reference for the preservation and sharing of these phages. Main Text Cronobacter sakazakii are facultative, anaerobic Gram-negative bacteria that exist widely in various foods and raw materials [1, 2]. In recent years, as a new foodborne pathogen, C.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0216288 A1 Chang (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2006/0216288 A1 Chang (43) Pub

    US 20060216288A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0216288 A1 Chang (43) Pub. Date: Sep. 28, 2006 (54) COMBINATIONS FOR THE TREATMENT OF Publication Classification CANCER (51) Int. Cl. (75) Inventor: David Chang, Calabasas, CA (US) A 6LX 39/395 (2006.01) A6II 3/55 (2006.01) Correspondence Address: A6II 3 L/4545 (2006.01) SESS is 2-C A61K 31/4439 (2006.01) ONE AMGEN CENTERY DRIVE A6II 3/44 (2006.O1 ) THOUSAND OAKS, CA 91320-1799 (US) (52) U.S. Cl. ................... 424/143.1: 514/352: 514/210.2: (73) Assignee: Amgen Inc., Thousand Oaks, CA 514/318: 514/340; 514/217.04 (21) Appl. No.: 11/386,271 (22) Filed: Mar. 21, 2006 (57) ABSTRACT Related U.S. Application Data This invention is in the field of pharmaceutical agents and (60) Provisional application No. 60/664,381, filed on Mar. specifically relates to compounds, compositions, uses and 22, 2005. methods for treating cancer. Patent Application Publication Sep. 28, 2006 Sheet 1 of 5 US 2006/0216288A1 Figure 1 -- Vehicle X Compound B, 10 mpk 1800 -- Antibody A, 20 ug 1600 Compound B, 10 mpk+ 1400 Antibody A, 20 ug 1200 1000 800 600 p = 0.0003 1/10 1110 1/10 p < 0.0001 v v v v v v V 174. 22 27 32 37 42 47 Time (days) V Antibody A injection Patent Application Publication Sep. 28, 2006 Sheet 2 of 5 US 2006/0216288A1 Figure 2 -- Vehicle 1800 X Compound B, 75 mpk 1600 th- Antibody A, 500 u 1400 dy 9 1200 Compound B, 75 mpk+ Antibody A, 500 ug 1000 800 600 V Antibodyy A, ipp injectionin 400 200 p < 0.0001 st 0.9515 V.
  • Ab Komplet 6.07.2018

    Ab Komplet 6.07.2018

    CONTENTS 1. Welcome addresses 2 2. Introduction 3 3. Acknowledgements 10 4. General information 11 5. Scientific program 16 6. Abstracts – oral presentations 27 7. Abstracts – poster sessions 99 8. Participants 419 1 EMBO Workshop Viruses of Microbes 2018 09 – 13 July 2018 | Wrocław, Poland 1. WELCOME ADDRESSES Welcome to the Viruses of Microbes 2018 EMBO Workshop! We are happy to welcome you to Wrocław for the 5th meeting of the Viruses of Microbes series. This series was launched in the year 2010 in Paris, and was continued in Brussels (2012), Zurich (2014), and Liverpool (2016). This year our meeting is co-organized by two partner institutions: the University of Wrocław and the Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences. The conference venue (University of Wrocław, Uniwersytecka 7-10, Building D) is located in the heart of Wrocław, within the old, historic part of the city. This creates an opportunity to experience the over 1000-year history of the city, combined with its current positive energy. The Viruses of Microbes community is constantly growing. More and more researchers are joining it, and they represent more and more countries worldwide. Our goal for this meeting was to create a true global platform for networking and exchanging ideas. We are most happy to welcome representatives of so many countries and continents. To accommodate the diversity and expertise of the scientists and practitioners gathered by VoM2018, the leading theme of this conference is “Biodiversity and Future Application”. With the help of your contribution, this theme was developed into a program covering a wide range of topics with the strongest practical aspect.